Showing 4071-4080 of 4951 results for "".
- Rare Pediatric Skin Conditions Often Get Expensive, Inconsistent Carehttps://practicaldermatology.com/news/rare-pediatric-skin-conditions-often-get-expensive-inconsistent-care/2457704/Children with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have high rates of complications — resulting in long and costly hospital stays — and that treatment strategies varied among health care providers, according to the first large-scale analysis, which is
- Jury Still Out on Environmental Effects of Chemical Sunscreenshttps://practicaldermatology.com/news/jury-still-out-on-environmental-effects-of-chemical-sunscreens/2457705/In the wake of Hawaiian legislation banning the sale and distribution of sunscreens containing oxybenzone and octinoxate because they may contribute to coral bleaching, new research reviews the available data on chemical ultraviolet filters found in U.S. sunscreens. The
- DermTech Initiating Study to Assess DNA Damage and Reversalhttps://practicaldermatology.com/news/dermtech-initiating-study-to-assess-dna-damage-and-reversal/2457712/DermTech, Inc. has initiated enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potentia
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- Alana Sine is New CFO at Merz North Americahttps://practicaldermatology.com/news/alan-sine-is-new-cfo-at-merz-north-america/2457719/Merz North America has appointed Alana Sine as Chief Financial Officer (CFO), Merz North America. Ms. Sine has served as interim CFO since March 2018. Ms. Sine will lead the finance function for North America, overseeing finan
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- Xact Nabs Best of Hot Topics at ASAPS 2018https://practicaldermatology.com/news/xact-nabs-best-of-hot-topics-at-asaps-2018/2457727/Cypris Medical, Inc.’s Xact technology took home the “Best of Hot Topics” award at the American Society for Aesthetic Plastic Surgery (ASAPS) meeting in New York. Xact technology is a minimally invasive face and neck lifting suturing d
- InMode: New EmbraceRF Solution Introduces Subdermal Adipose Remodelinghttps://practicaldermatology.com/news/inmode-new-embracerf-solution-introduces-subnormal-adipose-remodeling/2457733/Introducing the concept of Subdermal Adipose Remodeling, InMode Aesthetic Solutions is launching EmbraceRF to target the neck and face through a powerful combination of
- PellePharm Presents New Data in BCChttps://practicaldermatology.com/news/pellepharm-presents-new-data-in-bcc/2457731/PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs at the International Investigative Dermatology (IID) Meeting in Orlando, FL. The data, presented i